Aimee Schad , Abhinandan R Pakanati , Susan Woelich , Abhishek Chilkulwar
{"title":"布伦妥昔单抗韦多汀在血液透析中长期安全应用于一例经典霍奇金淋巴瘤患者","authors":"Aimee Schad , Abhinandan R Pakanati , Susan Woelich , Abhishek Chilkulwar","doi":"10.1016/j.cpccr.2023.100249","DOIUrl":null,"url":null,"abstract":"<div><p>Classical Hodgkin Lymphoma (cHL) is a B-cell derived lymphoma with excellent cure rates, however poor functional status or co-morbid conditions limit treatment options. Brentuximab vedotin (BV), a CD30 antibody drug conjugate, has an expanding role in cHL treatment. A 53-year-old man with multiple co-morbidities including end stage renal disease (ESRD) presenting with pancytopenia was found to have cHL. Not a candidate for intensive chemotherapy, he was safely maintained on intermittent BV for three years. Literature on prolonged BV use in hemodialysis is extremely limited. This case suggests BV as a safe treatment option for CD30 positive cHL in patients with ESRD on hemodialysis.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis\",\"authors\":\"Aimee Schad , Abhinandan R Pakanati , Susan Woelich , Abhishek Chilkulwar\",\"doi\":\"10.1016/j.cpccr.2023.100249\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Classical Hodgkin Lymphoma (cHL) is a B-cell derived lymphoma with excellent cure rates, however poor functional status or co-morbid conditions limit treatment options. Brentuximab vedotin (BV), a CD30 antibody drug conjugate, has an expanding role in cHL treatment. A 53-year-old man with multiple co-morbidities including end stage renal disease (ESRD) presenting with pancytopenia was found to have cHL. Not a candidate for intensive chemotherapy, he was safely maintained on intermittent BV for three years. Literature on prolonged BV use in hemodialysis is extremely limited. This case suggests BV as a safe treatment option for CD30 positive cHL in patients with ESRD on hemodialysis.</p></div>\",\"PeriodicalId\":72741,\"journal\":{\"name\":\"Current problems in cancer. Case reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current problems in cancer. Case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666621923000339\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621923000339","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis
Classical Hodgkin Lymphoma (cHL) is a B-cell derived lymphoma with excellent cure rates, however poor functional status or co-morbid conditions limit treatment options. Brentuximab vedotin (BV), a CD30 antibody drug conjugate, has an expanding role in cHL treatment. A 53-year-old man with multiple co-morbidities including end stage renal disease (ESRD) presenting with pancytopenia was found to have cHL. Not a candidate for intensive chemotherapy, he was safely maintained on intermittent BV for three years. Literature on prolonged BV use in hemodialysis is extremely limited. This case suggests BV as a safe treatment option for CD30 positive cHL in patients with ESRD on hemodialysis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
